GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » NonCurrent Deferred Liabilities

Galderma Group AG (FRA:PY30) NonCurrent Deferred Liabilities : €0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Galderma Group AG's non-current deferred liabilities for the quarter that ended in Dec. 2024 was €0 Mil.

Galderma Group AG NonCurrent Deferred Liabilities Historical Data

The historical data trend for Galderma Group AG's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG NonCurrent Deferred Liabilities Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
NonCurrent Deferred Liabilities
- -

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
NonCurrent Deferred Liabilities - - - -

Galderma Group AG NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines